Date: 2017-09-11
Type of information: Collaboration agreement
Compound: scheduling and logistics tool that automates the supply chain for adoptive cell therapy products that utilize tumor-infiltrating lymphocyte (TIL) technology.
Company: Iovance Biotherapeutics (USA - CA) TrakCel (USA - NJ)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details:
- • On September 11, 2017, Iovance Biotherapeutics and TrakCel announced a partnership to build a scheduling and logistics tool that automates the supply chain for Iovance's adoptive cell therapy products that utilize its tumor-infiltrating lymphocyte (TIL) technology. The TrakCel Solution will electronically link Iovance with clinical sites, contract manufacturing organizations and couriers to schedule and track TIL therapies for each patient. The TrakCel Solution is intended to help manage capacity utilization and throughput and will provide efficiencies in the delivery of TIL treatment.
- TrakCel is a designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel's solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to cell product delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.
Financial terms:
Latest news:
Is general: Yes
